Regarding "Limitations in the use of rifampicin-gelatin grafts against virulent organisms".
Naylor
A Ross
AR
Department of Surgery, Faculty of Medicine and Biological Sciences, Leicester Royal Infirmary, United Kingdom. arnaylor@hotmail.com
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000494:pharmacology*; D001807:Blood Vessel Prosthesis / Q000009:adverse effects; D004926:Escherichia coli / Q000187:drug effects; D005780:Gelatin; D006801:Humans; D016106:Methicillin Resistance; D016459:Prosthesis-Related Infections / Q000188:drug therapy*; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects
D000904:Antibiotics, Antitubercular; D005780:Gelatin; D012293:Rifampin